Difference between revisions of "Harisseh 2017 Basic Res Cardiol"
(3 intermediate revisions by 2 users not shown) | |||
Line 6: | Line 6: | ||
|journal=Basic Res Cardiol | |journal=Basic Res Cardiol | ||
|abstract=Reperfusion injury is responsible for an important part of myocardial infarct establishment due notably to triggering cardiomyocytes death at the first minutes of reperfusion. AZP-531 is an optimized analog of unacylated ghrelin currently in clinical development in several metabolic diseases. We investigated a potential cardioprotective effect of AZP-531 in ischemia/reperfusion (IR) and the molecular underlying mechanism(s) involved in this protection. ''In vivo'' postconditioning with AZP-531 in C57BL6 mouse IR model decreased infarct size. Western blot analysis on areas at risk from the different mouse groups showed that AZP-531 activates Akt, ERK1-2 as well as S6 and 4EBP1, mTORC1 effectors. We also showed an inhibition of caspase 3 cleavage and Bax translocation to the mitochondria. AZP-531 also stimulated the expression of antioxidants and was capable of decreasing mitochondrial H2O2 production, contributing to the reduction of ROS accumulation. AZP-531 exhibits cardioprotective effect when administrated for postconditioning in C57BL6 mouse IR model. Treatment with AZP-531 rescued the myocardium from cell death at early reperfusion by stimulating protein synthesis, inhibiting Bax/caspase 3-induced apoptosis as well as ROS accumulation and oxidative stress-induced necrosis. AZP-531 may prove useful in the treatment of IR injury. | |abstract=Reperfusion injury is responsible for an important part of myocardial infarct establishment due notably to triggering cardiomyocytes death at the first minutes of reperfusion. AZP-531 is an optimized analog of unacylated ghrelin currently in clinical development in several metabolic diseases. We investigated a potential cardioprotective effect of AZP-531 in ischemia/reperfusion (IR) and the molecular underlying mechanism(s) involved in this protection. ''In vivo'' postconditioning with AZP-531 in C57BL6 mouse IR model decreased infarct size. Western blot analysis on areas at risk from the different mouse groups showed that AZP-531 activates Akt, ERK1-2 as well as S6 and 4EBP1, mTORC1 effectors. We also showed an inhibition of caspase 3 cleavage and Bax translocation to the mitochondria. AZP-531 also stimulated the expression of antioxidants and was capable of decreasing mitochondrial H2O2 production, contributing to the reduction of ROS accumulation. AZP-531 exhibits cardioprotective effect when administrated for postconditioning in C57BL6 mouse IR model. Treatment with AZP-531 rescued the myocardium from cell death at early reperfusion by stimulating protein synthesis, inhibiting Bax/caspase 3-induced apoptosis as well as ROS accumulation and oxidative stress-induced necrosis. AZP-531 may prove useful in the treatment of IR injury. | ||
|keywords=Bax/Caspase 3 apoptosis, Cardiomyocyte, ''In vivo'' Ischemia–Reperfusion, Mitochondria, Oxidative stress, Unacylated ghrelin | |keywords=Bax/Caspase 3 apoptosis, Cardiomyocyte, ''In vivo'' Ischemia–Reperfusion, Mitochondria, Oxidative stress, Unacylated ghrelin, Amplex Red | ||
|mipnetlab=FR Lyon Ovize M | |mipnetlab=FR Lyon Ovize M | ||
}} | }} | ||
Line 14: | Line 14: | ||
|organism=Mouse | |organism=Mouse | ||
|tissues=Heart | |tissues=Heart | ||
|preparations=Permeabilized cells | |||
|couplingstates=OXPHOS, ET | |||
|pathways=N, S, CIV, ROX | |||
|instruments=Oxygraph-2k | |instruments=Oxygraph-2k | ||
}} | }} |
Latest revision as of 10:11, 22 November 2017
Harisseh R, Pillot B, Gharib A, Augeul L, Gallo-Bona N, Ferrera R, Loufouat J, Delale T, Allas S, Abribat T, Crola Da Silva C, Ovize M (2017) Unacylated ghrelin analog prevents myocardial reperfusion injury independently of permeability transition pore. Basic Res Cardiol 112:4. |
Harisseh R, Pillot B, Gharib A, Augeul L, Gallo-Bona N, Ferrera R, Loufouat J, Delale T, Allas S, Abribat T, Crola Da Silva C, Ovize M (2017) Basic Res Cardiol
Abstract: Reperfusion injury is responsible for an important part of myocardial infarct establishment due notably to triggering cardiomyocytes death at the first minutes of reperfusion. AZP-531 is an optimized analog of unacylated ghrelin currently in clinical development in several metabolic diseases. We investigated a potential cardioprotective effect of AZP-531 in ischemia/reperfusion (IR) and the molecular underlying mechanism(s) involved in this protection. In vivo postconditioning with AZP-531 in C57BL6 mouse IR model decreased infarct size. Western blot analysis on areas at risk from the different mouse groups showed that AZP-531 activates Akt, ERK1-2 as well as S6 and 4EBP1, mTORC1 effectors. We also showed an inhibition of caspase 3 cleavage and Bax translocation to the mitochondria. AZP-531 also stimulated the expression of antioxidants and was capable of decreasing mitochondrial H2O2 production, contributing to the reduction of ROS accumulation. AZP-531 exhibits cardioprotective effect when administrated for postconditioning in C57BL6 mouse IR model. Treatment with AZP-531 rescued the myocardium from cell death at early reperfusion by stimulating protein synthesis, inhibiting Bax/caspase 3-induced apoptosis as well as ROS accumulation and oxidative stress-induced necrosis. AZP-531 may prove useful in the treatment of IR injury. • Keywords: Bax/Caspase 3 apoptosis, Cardiomyocyte, In vivo Ischemia–Reperfusion, Mitochondria, Oxidative stress, Unacylated ghrelin, Amplex Red
• O2k-Network Lab: FR Lyon Ovize M
Labels: MiParea: Respiration
Stress:Ischemia-reperfusion, Permeability transition Organism: Mouse Tissue;cell: Heart Preparation: Permeabilized cells
Coupling state: OXPHOS, ET
Pathway: N, S, CIV, ROX
HRR: Oxygraph-2k